New drug stops growth of aggressive breast cancer.
Posted by giorgiobertin on February 6, 2024
A promising drug could lead to a new treatment for the most aggressive form of breast cancer, which affects thousands of women every year. One studio preclinical conducted byUniversity of Adelaide found that the new drug successfully inhibits the growth of triple-negative breast cancer without toxic side effects.
L-R: Triple negative breast cancer cells before treatment and after treatment.
The drug CDDD11-8 it could represent a breakthrough in the treatment of triple-negative breast cancer, according to Professor Theresa Hickey of the University of Adelaide. This drug, designed to be taken orally, works by targeting a specific protein in the tumor called cdk9, effectively stopping the growth of tumor cells. The results of the preclinical study are promising and suggest that this drug could be the key to improving survival rates for patients with this aggressive form of breast cancer.
Although further development is still needed before moving to human trials, researchers are optimistic about the therapeutic potential of this drug.
Read the full text of the article:
Selective inhibition of CDK9 in triple negative breast cancer.
Mustafa , EH , Laven-Law , G. , Kikhtyak , Z. et al.
Oncogene 43, 202–215 (2024).
Source: University of Adelaide
This entry was posted on febbraio 6, 2024 a 6:10 am and is filed under News-research. Tagged: pharmacology, gynecology, oncology. You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a responseor trackback from your own site.